A recent analysis using family history weighting and co-observation classification modeling indicated that BRCA1 c.594-2A 〉 C (IVS9-2A 〉 C), previously described to cause exon 10 skipping (a truncating alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess pathogenicity of c.594-2A 〉 C. The combined odds for causality considering case-control, segregation and breast tumor pathology information was 3.23 x 10-8 Our data indicate that c.594-2A 〉 C is always in cis with c.641A 〉 G. The spliceogenic effect of c.[594-2A 〉 C;641A 〉 G] was characterized using RNA analysis of human samples and splicing minigenes. As expected, c.[594-2A 〉 C; 641A 〉 G] caused exon 10 skipping, albeit not due to c.594-2A 〉 C impairing the acceptor site but rather by c.641A 〉 G modifying exon 10 splicing regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce detectable levels of full-length transcripts, with a per allele BRCA1 expression profile composed of approximately 70-80% truncating transcripts, and approximately 20-30% of in-frame Delta9,10 transcripts predicted to encode a BRCA1 protein with tumor suppression function.We confirm that BRCA1c.[594-2A 〉 C;641A 〉 G] should not be considered a high-risk pathogenic variant. Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of variants in disease-causing genes.
Type of Publication:
Journal article published